MedTrace Logo

Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research

NCT04590976 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2023-02-08

No results posted yet for this study

Summary

Systemic therapy (i.e Androgen Deprivation Therapy with Docetaxel, Enzalutamide, Apalutamide or Abiraterone Acetate) has increased overall survival in men with hormone-sensitive metastatic prostate cancer.

Novel local cytoreductive treatments and metastasis directed therapy are being evaluated, these can confer additional harm, but might improve survival.

We aim to elicit men's preferences for and willingness to accept trade-offs between potential improved survival and cytoreductive treatment risks using a 'discrete choice experiment'.

Conditions

  • Prostate Cancer Metastatic
  • Radiotherapy Side Effect
  • Surgery
  • Urologic Cancer
  • Quality of Life
  • Patient Satisfaction
  • Health Care Utilization

Interventions

OTHER

Semi-Structured Interview Healthcare Professional

Interview

OTHER

Semi-Structured Interview Patients

Interview

OTHER

Think Aloud Interview Patients

Interview

OTHER

Discrete Choice Experiment (DCE) Patients

DCE Questionnaire

Sponsors & Collaborators

  • University of Aberdeen

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Hashim Ahmed, PhD, FRCS · Imperial College London

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04590976 on ClinicalTrials.gov